Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05640999 · ClinicalTrials.gov registry record · Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

A Phase 2 study of Endometrial Cancer, sponsored by Canadian Cancer Trials Group.

Recruiting
Registry status
Phase 2
Development phase
393
Enrollment target
20
Study locations

NCT05640999 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 393 participants, below the 522-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05640999, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.

RECRUITING
Registry status
Phase 2
Development phase
393 participants
Enrollment target
20
Study locations

Study Summary

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC

Conditions Studied

Endometrial Cancer

Interventions

  • OTHER Observation
  • RADIATION Vaginal brachytherapy
  • RADIATION Adjuvant radiotherapy (EBRT +/- brachytherapy)

Study Locations (20)

Florida

  • University of Miami School of Medicine - Miami
  • Sarasota Memorial Hospital - Venice - N. Venice
  • Florida Cancer Specialists - Sarasota Downtown - Sarasota
  • First Physicians Group-Sarasota - Sarasota
  • Sarasota Memorial Hospital - Sarasota
  • Sarasota Memorial Health Care Centre - Sarasota
  • Florida Cancer Specialists - Venice Pinebrook - Venice

Georgia

  • Grady Health System - Atlanta
  • Emory University Hospital Midtown - Atlanta
  • Piedmont Hospital - Atlanta
  • Emory University Hospital Winship Cancer Institute - Atlanta
  • Emory Saint Josephs Hospital - Atlanta
  • Emory Decatur Hospital - Decatur

California

  • Cedars-Sinai Medical Center - Los Angeles
  • Huntington Memorial Hospital - Pasadena
  • Sutter Medical Center Sacramento - Sacramento

Colorado

  • UCHealth University of Colorado Hospital - Aurora
  • AdventHealth Porter - Denver

Alaska

  • Alaska Womens Cancer Care - Anchorage

Arizona

  • University of Arizona Cancer Center - Tucson

Trial Details

FieldValue
Enrollment Target 393 participants
Start Date 2022-12-19
Est. Completion 2029-06-30
Phase Phase 2

Sponsor

Canadian Cancer Trials Group

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05640999

The ClinicalTrials.gov registry entry for NCT05640999 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 522-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (25% lower). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Observation is the first listed.

NCT05640999 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, California.

Frequently Asked Questions

What is clinical trial NCT05640999 about?

NCT05640999 is a clinical study titled "Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER". This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N...

What is the current status of trial NCT05640999?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 393 participants. The study started on 2022-12-19. Estimated completion is 2029-06-30.

What conditions does trial NCT05640999 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT05640999?

The interventions under investigation include: Observation (OTHER), Vaginal brachytherapy (RADIATION), Adjuvant radiotherapy (EBRT +/- brachytherapy) (RADIATION).

Who is sponsoring clinical trial NCT05640999?

This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05640999 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.